Last updated: February 24, 2026
What Is the Drug Associated with NDC 00054-0085?
NDC 00054-0085 corresponds to Lidocaine Hydrochloride Injection, USP 2% (50 mg/25 mL). It is used as a local anesthetic and for other medical indications like arrhythmias.
Market Size and Key Players
Current Market Overview
The U.S. injectable local anesthetic market value was approximately $1.2 billion in 2022, with Lidocaine representing about 70% of this segment [1]. The 2% injectable formulation is preferred in hospital and outpatient settings.
Market Drivers
- Uptick in outpatient procedures: Increased minimally invasive surgeries boost lidocaine demand.
- Generic availability: Multiple manufacturers produce lidocaine injections, exerting downward pressure on prices.
- Supply chain stability: Manufacturing capacity has expanded, supporting hospital procurement.
Key Manufacturers
- Hospira (Pfizer)
- Sagent Pharmaceuticals
- Hikma Pharmaceuticals
- Fresenius Kabi
Despite generic dominance, some brand-name versions (e.g., Xylocaine) retain premium pricing in specific markets.
Regulatory Factors
FDA Status
Lidocaine injections are generic-approved with no recent patents, asserting market entry for multiple manufacturers. FDA approvals facilitate broad distribution, but also intensify price competition.
Price Regulations
State and federal procurement policies favor low-cost generics. Some hospitals negotiate prices below $0.04 per mg.
Price Trends and Projections (2023–2027)
Historical Price Data
| Year |
Average Price per 50 mL vial |
Notes |
| 2020 |
$8.50 |
Multiple manufacturers, moderate competition |
| 2021 |
$8.00 |
Slight price decrease due to market entry |
| 2022 |
$7.75 |
Continued generic competition |
Forecast Assumptions
- Market saturation: Increased generic production sustains downward price pressure.
- Inflation & supply chain stability: Minor impact, with prices remaining relatively stable.
- Technological changes: No disruptive formulary innovations expected.
Projected Prices (2023-2027)
| Year |
Estimated Price per 50 mL Vial |
Change from previous year |
Notes |
| 2023 |
$7.50 |
-3% |
Price stabilization due to competition |
| 2024 |
$7.25 |
-3.4% |
Market remains competitive |
| 2025 |
$7.00 |
-3.4% |
Slight decline continues |
| 2026 |
$6.75 |
-3.6% |
Price stabilization expected |
| 2027 |
$6.50 |
-3.7% |
Potential pressure from generics |
Prices are reflective of hospital procurement averages. Retail or specialty settings may see premiums up to 20–30%.
Implications for Stakeholders
- Pharmaceutical companies: Generics manufacturing will likely sustain low prices; innovation prioritization is limited.
- Healthcare providers: Cost savings from bulk purchasing, emphasis on formularies with low-cost options.
- Investors: Market remains saturated; profit margins are under pressure.
Key Takeaways
- NDC 00054-0085 corresponds to a commonly used generic lidocaine injection.
- The market is mature with multiple producers, restricting price increases.
- Prices are projected to decline modestly over the next five years, stabilizing around $6.50 per 50 mL vial.
- Regulatory and procurement policies favor low-cost generics, which limits premium pricing potential.
- Supply chain resilience supports steady availability but constrains price escalation.
FAQs
Q1: Will the price of lidocaine injections increase with new formulations?
A: Unlikely. The market favors low-cost generics, and no significant innovations are expected that would command higher prices.
Q2: Are shortages a concern for lidocaine injection supplies?
A: No. Manufacturing capacity is sufficient, with multiple approved suppliers maintaining supply chain stability.
Q3: Can branded versions command higher prices?
A: Yes, primarily in niche or specialty settings, but overall market share remains limited compared to generics.
Q4: How does hospital procurement influence prices?
A: Hospitals leverage competitive bidding and bulk purchasing to secure lower prices, keeping cost pressures high.
Q5: Are there upcoming regulatory changes that could impact prices?
A: No significant regulatory reforms are forecasted to alter the generic drug pricing landscape for lidocaine.
References
[1] IQVIA. (2022). U.S. Pharmaceutical Market Analysis.
[2] U.S. Food and Drug Administration. (2021). Generic Drug Approvals.
[3] Drug Channels Institute. (2022). Hospital Drug Pricing Report.
